Stanford inventors have developed and fabricated biodegradable and biocompatible polysaccharide hydrogel optical fibers for fiber optic sensing and light transmission in biomedical applications like antigen detection, tracking cellular events, and optogenetics.
A common hurdle for many drug delivery applications is getting the desired compounds to the targeted cells or receptors. Additional barriers of achieving the therapeutic drug concentration and necessary drug diffusion are also present even after successful targeted delivery.
Recent studies have linked microglia damage to various neurodegenerative and aging brain diseases. Relatedly, bone marrow transplantation has been shown to result in incorporation of macrophages into the brain, but the incorporation is variable, slow and inefficient.
Researchers in the laboratories of Prof. Stanley Cohen and Prof Tzu-Hao Cheng have discovered that Supt4h is a potential therapeutic target for reducing toxicity and restoring the functionality of deleterious proteins in Huntington's (HD) and other polyQ diseases.
Dr. Stanley Cohen and colleagues have identified small molecular compounds that may be useful in the treatment of nucleotide repeat diseases. A well-known nucleotide repeat disorder is Huntington's disease.
Researchers in Prof. Karl Deisseroth's laboratory have developed a portfolio of microbial opsin proteins that can be used for precise and modular photosensitization components that enable optical control of specific cellular processes.
Researchers in Dr. Karl Deisseroth's lab have developed a selective approach to treat anxiety. Anxiety is characterized by several features that are coordinately regulated by diverse neuronal system outputs.
Researchers in Prof. Karl Deisseroth's laboratory have combined optogenetics with functional magnetic resonance imaging (fMRI) to enable highly specific in vivo analysis of brain circuits.